Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.7326/L16-0627 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pioglitazone Modulates Microglia M1/M2 Polarization Through PPAR-γ Pathway and Exerts Neuroprotective Effects in Experimental Subarachnoid Hemorrhage.
Mol Neurobiol
December 2024
Department of Neurosurgery, The Affiliated Yixing Hospital of Jiangsu University, Jiangsu Province, Yixing, 214200, China.
Subarachnoid hemorrhage (SAH), a subtype of hemorrhagic stroke primarily resulting from the rupture of intracranial aneurysms, remains a significant contributor to disability and mortality, notwithstanding advancements in treatment. This study investigates the neuroprotective effects of pioglitazone in SAH, focusing on the PPAR-γ pathway and its potential role in mitigating early brain injury (EBI) following SAH. Neuroprotective efficacy was assessed through neurobehavioral assessment, brain water content analysis, TUNEL, immunofluorescence, western blotting, and inflammatory factor assay.
View Article and Find Full Text PDFChronic glial activation and behavioral alterations induced by acute/subacute pioglitazone treatment in a mouse model of traumatic brain injury.
Brain Behav Immun
January 2025
University of Nebraska Medical Center, College of Medicine, Department of Neurological Sciences, Omaha, NE, USA. Electronic address:
Article Synopsis
- Traumatic brain injury (TBI) is a major cause of injury-related death and disability in the U.S., and managing neuroinflammation early is crucial for treatment.
- Pioglitazone, a drug that may reduce inflammation after TBI, shows potential but also has unknown long-term effects that can worsen brain conditions.
- Research in mice indicates that acute/subacute treatment with pioglitazone leads to negative outcomes, including brain damage and behavior changes, highlighting the need for sex-based considerations and further investigation before clinical use for TBI.
The effects of PPARγ agonists on long‑termpotentiation and apoptosis in the hippocampusarea of juvenile hypothyroid rats.
Acta Neurobiol Exp (Wars)
June 2024
Bio Environmental Health Hazards Research Center, Jiroft University of Medical Sciences, Jiroft, Iran.
The aim of the present study was to evaluate the effect of rosiglitazone (RSG) or pioglitazone (POG) on the synaptic plasticity, neuronal apoptosis, brain-derived neurotrophic factor (BDNF), and nitric oxide (NO) metabolites in the hippocampus of juvenile hypothyroid rats. The animals were divided into four groups: control; propylthiouracil (PTU), 0.05% dose in drinking water for 42 days; PTU-POG; and PTU-RSG.
View Article and Find Full Text PDFNon-alcoholic fatty liver disease in type 2 diabetes: Emerging evidence of benefit of peroxisome proliferator-activated receptors agonists and incretin-based therapies.
World J Methodol
June 2024
Department of Endocrinology, All India Institute of Medical Sciences, Bhubaneswar, Bhubaneswar 751019, Odisha, India.
Nonalcoholic fatty liver disease (NAFLD) is a global epidemic, affecting more than half of the people living with type 2 diabetes (T2D). The relationship between NAFLD and T2D is bidirectional and the presence of one perpetuates the other, which significantly increases the hepatic as well as extrahepatic complications. Until recently, there was no approved pharmacological treatment for NAFLD/ nonalcoholic steatohepatitits (NASH).
View Article and Find Full Text PDFLong-term effects of different hypoglycemic drugs on carotid intima-media thickness progression: a systematic review and network meta-analysis.
Front Endocrinol (Lausanne)
June 2024
Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Objective: The progression of carotid intima-media thickness (cIMT) can partially predict the occurrence of future cardiovascular events. This network meta-analysis compared the effects of 14 antidiabetic drugs (acarbose, alogliptin, exenatide, glibenclamide, glimepiride, ipragliflozin, metformin, nateglinide, pioglitazone, rosiglitazone, sitagliptin, tofoglifozin, troglitazone, voglibose) on the progression of cIMT.
Method: PubMed, EMBASE, Cochrane Library, and Web of Science were searched to screen all clinical trials of treatment of cIMT with hypoglycemic agents before March 1, 2024.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!